$CVKD News

Cadrenal Therapeutics Matthew K. Szot Steps Down As CFO Effective May 28, 2026; Co. Appoints Quang X. Pham As Interim CFO

Cadrenal Therapeutics Announces Participation In BIO 2026; To Host Partnering Meetings To Discuss Development And Commercialization Opportunities For Differentiated Pipeline, Headlined By CAD-1005 And Tecarfarin

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

CVKD: Designing Phase 3 Trial for CAD-1005 in HIT

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Cadrenal Therapeutics Q1 EPS $(1.04) Beats $(1.62) Estimate

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Cadrenal Therapeutics Receives FDA Guidance For Phase 3 Trial Of CAD-1005 Heparin-Induced Thrombocytopenia Treatment

Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program

CVKD: Results Show 12-LOX Inhibition Targets Inflammation from Obesity and Type 2 Diabetes

Watching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $25 Price Valuation

Watching Cadrenal Therapeutics; Zacks Small-Cap Research Gives Stock $25 Price Valuation

HC Wainwright & Co. Maintains Buy on Cadrenal Therapeutics, Lowers Price Target to $13

Cadrenal Therapeutics shares are trading higher. The company reported Q4 financial results.

Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting

Cadrenal Therapeutics Q4 EPS $(1.41) Misses $(1.18) Estimate

OTC Markets Hosts Virtual Investor Presentation with Quang Pham, Chairman and CEO of Cadrenal Therapeutics, and David Bautz, PhD, Senior Analyst at Zacks SCR

Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes

Cadrenal Therapeutics Highlights Recent Scientific Findings Demonstrating Potential Of 12-Lipoxygenase Inhibitor, CAD-1005, To Target Inflammatory Consequences Of Obesity And Type 2 Diabetes

Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion